



**Fig. S4.  $^{18}\text{F}$ -Fluorodeoxyglucose ( $^{18}\text{F}$ -FDG)-CT/PET of subjects UPN031 and UPN033.** **A**, For UPN031, the glucose (FDG)-CT/PET scan post-T cell administration demonstrated low FDG uptake in the enhancing mass seen on the brain MRI (reference Fig. 3). **B**, For UPN033, glucose (FDG)-CT/PET scans pre- and post-T cell administration (i.e., during week 3 rest/restaging; reference Fig. 1A) identifies FDG-avid region across the splenium of the corpus callosum (red arrow) rather than adjacent to the CAR-treated tumor cavity.